Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
Dirk Arnold(CUF Porto Hospital), B. Lueza(Université Paris-Sud), Jean-Yves Douillard(European Society for Medical Oncology), Marc Peeters(Antwerp University Hospital), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Alan P. Venook(University of California, San Francisco), Volker Heinemann, Eric Van Cutsem(KU Leuven), Jean‐Pierre Pignon(Université Paris-Sud), Josep Tabernero(Universitat Autònoma de Barcelona), Andrés Cervantes(Universitat de València), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli")
Cited by 830Open Access
Abstract
Related Papers
Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer
Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al.|New England Journal of Medicine|2013|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al.|The Lancet Oncology|2014|1.7k